BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koleva-Kolarova RG, Greuter MJ, van Kruchten M, Vermeulen KM, Feenstra T, Buskens E, Glaudemans AW, de Vries EF, de Vries EG, Hospers GA, de Bock GH. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. Br J Cancer 2015;112:1617-25. [PMID: 25880006 DOI: 10.1038/bjc.2015.138] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Wawruszak A, Borkiewicz L, Okon E, Kukula-Koch W, Afshan S, Halasa M. Vorinostat (SAHA) and Breast Cancer: An Overview. Cancers (Basel) 2021;13:4700. [PMID: 34572928 DOI: 10.3390/cancers13184700] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
2 Katzenellenbogen JA. PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging. Cancers (Basel) 2020;12:E2020. [PMID: 32718075 DOI: 10.3390/cancers12082020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Boers J, de Vries EFJ, Glaudemans AWJM, Hospers GAP, Schröder CP. Application of PET Tracers in Molecular Imaging for Breast Cancer. Curr Oncol Rep 2020;22:85. [PMID: 32627087 DOI: 10.1007/s11912-020-00940-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Peterson LM, Kurland BF, Yan F, Jiresova AN, Gadi VK, Specht JM, Gralow JR, Schubert EK, Link JM, Krohn KA, Eary JF, Mankoff DA, Linden HM. 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer. J Nucl Med 2021;62:184-90. [PMID: 32591490 DOI: 10.2967/jnumed.120.244459] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
5 Chae SY, Son HJ, Lee DY, Shin E, Oh JS, Seo SY, Baek S, Kim JY, Na SJ, Moon DH. Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. EJNMMI Res 2020;10:54. [PMID: 32448947 DOI: 10.1186/s13550-020-00643-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 van Uden DJP, Prins MW, Siesling S, de Wilt JHW, Blanken-Peeters CFJM, Aarntzen EHJG. [18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review. Crit Rev Oncol Hematol 2020;151:102943. [PMID: 32416347 DOI: 10.1016/j.critrevonc.2020.102943] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
7 Katzenellenbogen JA. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review. Nucl Med Biol 2021;92:24-37. [PMID: 32229068 DOI: 10.1016/j.nucmedbio.2020.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
8 Kumar M, Salem K, Tevaarwerk AJ, Strigel RM, Fowler AM. Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer. J Nucl Med 2020;61:172-6. [PMID: 31732674 DOI: 10.2967/jnumed.119.228858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
9 de Vries EGE, Kist de Ruijter L, Lub-de Hooge MN, Dierckx RA, Elias SG, Oosting SF. Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. Nat Rev Clin Oncol 2019;16:241-55. [PMID: 30479378 DOI: 10.1038/s41571-018-0123-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
10 Koleva-Kolarova RG, Greuter MJW, Feenstra TL, Vermeulen KM, de Vries EFJ, Parkin D, Buskens E, de Bock GH. Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study. Oncotarget 2018;9:19836-46. [PMID: 29731987 DOI: 10.18632/oncotarget.24869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Weissleder R, Schwaiger MC, Gambhir SS, Hricak H. Imaging approaches to optimize molecular therapies. Sci Transl Med 2016;8:355ps16. [PMID: 27605550 DOI: 10.1126/scitranslmed.aaf3936] [Cited by in F6Publishing: 65] [Reference Citation Analysis]
12 Sonnenblick A, Pondé N, Piccart M. Metastatic breast cancer: The Odyssey of personalization. Mol Oncol 2016;10:1147-59. [PMID: 27430154 DOI: 10.1016/j.molonc.2016.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
13 Liao GJ, Clark AS, Schubert EK, Mankoff DA. 18 F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications. J Nucl Med 2016;57:1269-75. [DOI: 10.2967/jnumed.116.175596] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
14 van Es SC, Venema CM, Glaudemans AW, Lub-de Hooge MN, Elias SG, Boellaard R, Hospers GA, Schröder CP, de Vries EG. Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. J Nucl Med 2016;57 Suppl 1:96S-104S. [PMID: 26834109 DOI: 10.2967/jnumed.115.157974] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
15 Gambert P, Lallemant C, Andre JL, Athias A, Bourquard R, Pierson M, Padieu P. Cholesterol content of serum lipoprotein fractions in children maintained on chronic hemodialysis. Clin Chim Acta. 1981;110:295-300. [PMID: 7226533 DOI: 10.3390/cancers12040821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]